Skip to main content

Advertisement

Figure 10 | Journal of Neuroinflammation

Figure 10

From: Glimepiride reduces CD14 expression and cytokine secretion from macrophages

Figure 10

Glimepiride induced immunosuppression is reversed by pCMPS. (A) The amounts of CD14 in RAW 264 cells treated for 1 hour with control medium or 5 μM glimepiride in the presence of control medium (□) or 200 μM pCMPS (■). Values are means ± SD from triplicate experiments performed 4 times, n = 12. *CD14 significantly greater than those of cells treated with glimepiride. (B) The concentrations of TNF produced by RAW 264 cells pre-treated with control medium (□), 5 μM glimepiride (■), or 5 μM glimepiride and 200 μM pCMPS (striped bars) and incubated with 50 μM PrP82-146, 50 μM Aβ1–42 or 50 μM αSN. Values are means ± SD from triplicate experiments performed 4 times, n = 12. *TNF significantly less than control cells incubated with peptides. (C) The concentrations of TNF produced by RAW 264 cells pre-treated with control medium (), 5 μM glimepiride () or 5 μM glimepiride and 200 μM pCMPS () and incubated with LPS as shown. Values are means ± SD from triplicate experiments performed 4 times, n = 12. (D) The concentrations of TNF produced by microglial cells pre-treated with control medium (□), 5 μM glimepiride (■), or 5 μM glimepiride and 200 μM pCMPS (striped bars) and incubated with 50 μM PrP82-146 or 50 μM Aβ1–42. Values are means ± SD from triplicate experiments performed twice, n = 6. *TNF significantly less than control cells incubated with peptides.

Back to article page